The Phase 3 Universal Flu Vaccine J OSHUA P HILLIPSON A PRIL 2 , 2019

The Phase 3 Universal Flu Vaccine J OSHUA P HILLIPSON A PRIL 2 , 2019

This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction . All statements in this communication, other than those relating to historical facts, are "forward - looking statements" within the meaning of the United States Private Litigation Reform Act of 1995 . You can identify forward - looking statements by terms including anticipates, '' believes, '' could, '' estimates, '' expects, '' intends, '' may, '' plans, '' potential, '' predicts, '' projects, '' should, '' will, '' would, '' and similar expressions intended to identify forward - looking statements . These forward - looking statements relate to our business and financial performance and condition, as well as our plans, strategies, objectives and expectations for our business, operations and financial performance and condition . However, these forward - looking statements are not guarantees of future performance and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward - looking statements . Important factors that could cause actual results to differ materially from our expectations include, among others : the risk that drug development involves a lengthy and expensive process with uncertain outcome ; BiondVax's ability to successfully develop and commercialize its vaccine ; the length, progress and results of any clinical trials ; the introduction of competing products ; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry ; the difficulty in receiving the regulatory approvals to commercialize BiondVax's products ; the difficulty in evaluating business prospects ; the adequacy of available cash resource and the ability to raise capital when needed ; the regulatory environment and changes in the health policies and regimes in the countries in which we operate ; changes in the global pharmaceutical industry ; changes in customers ' budgeting priorities ; European Medicines Agency and other regulatory authority approvals ; natural disasters ; labor disputes ; rising interest rates ; general market, political or economic conditions in the countries in which we operate ; pension and health insurance liabilities ; volatility or crises In the financial market ; arbitration, litigation and regulatory proceedings ; and war or acts of terror . Forward - looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties . You should not unduly rely on any forward - looking statements . Although we believe that the expectations reflected in the forward - looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward - looking statements will be achieved or will occur . The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 20 - F for the year ended December 31 , 2017 filed with the U . S . Securities and Exchange Commission, or SEC, which is available on the SEC ' s website, www . sec . gov, and in the Company ' s periodic filings with the SEC . Readers are urged to carefully review and consider the various disclosures made in the Company ' s SEC reports, which are designed to advise interested parties of the risks and factors that may affect its business, financial condition, results of operations and prospects . These forward - looking statements speak only as of the date of this presentation, and we assume no obligation to update or revise these forward - looking statements for any reason, whether as a result of new information, future events or otherwise, except as required by law . S AFE H ARBOR S TATEMENT One For All : The Universal Flu Vaccine

Flu cases: up to 20% or 1.5 billion Severe illness: 3 - 5 million Deaths : up to 650,000 2 The Flu: A Serious Public Health Challenge A S EASONAL P ROBLEM A P ANDEMIC T HREAT At - risk Seniors: 80 % of deaths & most hospitalizations 3 High economic burden: Over $ 87 B including $ 56 B in elderly 4 USA: Up to 80,000 deaths and 900,000 hospitalizations 5 P ANDEMIC F LU New pandemic strain: When? Where?... Which? Higher morbidity & mortality worldwide 1 WHO: http://www.who.int/influenza_vaccines_plan/objectives/objective 2 /en/ and https://en.wikipedia.org/wiki/Influenza_vaccine#Uptake; 2 WHO: http://www.who.int/news - room/detail/ 14 - 12 - 2017 - up - to - 650 - 000 - people - die - of - respiratory - diseases - linked - to - seasonal - flu - each - year (varies annually); 3 Vaccine journal: www.sciencedirect.com/science/article/pii/S 0264410 X 15002315 , Table 3 ; 4 Molinari et. al, The annual impact of seasonal influenza in the US, Vaccine 25 ( 2007 ) 5086 - 5096 ; 5 CDC: www.cdc.gov/flu/about/disease/burden.htm and https://www.nytimes.com/ 2018 / 10 / 01 /health/flu - deaths - vaccine.html Image: Influenza victims crowd into an emergency hospital near Fort Riley, Kansas in this 1918 file photo. National Museum of Health S EASONAL F LU - D ESPITE A NNUAL V ACCINE PRODUCTION ( 500 MILLION DOSES 1 )

38 % 40% 48 % 19 % 52 % 49 % 47 % 60 % 56 % 41% 37 % 52 % 21 % 10 % 2017-18 2016-17 2015-16 2014-15 2013-14 2012-13 2011-12 2010-11 2009-10 2008-09 2007-08 2006-07 2005-06 2004-05 C URRENT V ACCINE F ALLS S HORT : T HE M ISMATCH 1 VE data: CDC, including http://www.cdc.gov/flu/professionals/vaccination/effectiveness - studies.htm [Retrieved 18 .Feb. 2018 ] 2 World Health Organization: http://www.who.int/immunization/research/meetings_workshops/ 2 a_Graham_pdvac_sept 14 .pdf Why current solutions fall short Past strains selection Mismatch phenomenon Previous season ' s vaccine will not necessarily protect against next season ' s flu strains 4 - 6 month production lag The Flu Virus: Frequent and Unpredictable Mutations Seasonal Flu Vaccine Effectiveness 1 Average 40 %, Elderly as low as 9 % Measles, Rubella, Diphtheria, Tetanus, etc. 95 % - 99 % Protection

BiondVax operational 2005 Technology developed by Prof. Ruth Arnon Head BiondVax ' s SAB Mid 90 ' s Co - Inventor of One For All : The Universal Flu Vaccine 2018 - Pivotal Clinical Efficacy Phase 3 trial (EU) - Mid - size manufacturing plant construction - USA NIH - sponsored Phase 2 Solid Science, Advanced Clinical Stage, Strong IP Nasdaq: BVXV 2015 M EETING M ILESTONES & C ATALYSTS TASE June 2007 Delisted 2018 6 Successful Clinical Trials Two Phase 1 / 2 & Four Phase 2 FDA IND / EMA SA 698 young adult to elderly participants M - 001 shown to be safe and immunogenic in all studies

M - 001: A C OMMON D ENOMINATOR OF F LU V IRUSES Target Common Regions: Nine common flu regions (epitopes) connected to make one recombinant protein (M - 001 ) produced in E.coli H em A gglutinin (HA) N ucleo P rotein (NP) M atrix protein (M 1 ) One For All : The Universal Flu Vaccine BiondVax ' s M - 001 Key Advantages Existing vaccines Universal: Broad coverage types A&B Strain specific Single formulation enabling year - round vaccination New vaccine every year Quick, robust year - round production through E.coli fermentation (6 - 8 weeks) Long (4 - 6 month) production cycle Induces cellular (CMI) and enhances humoral (HAI priming effect) immune response to flu Limited vaccine effectiveness Shelf life up to 24 months at 2 - 8 C (testing is ongoing) and 6 months at ~25 C (room temperature) Not applicable, since new vaccine every season Now in prefilled syringes

Flu viruses are intracellular parasites Most of their lifecycle occurs inside our cells, thus are out of the reach of antibodies Our immune system mainly fights viral infection with cellular immunity via cytokines M - 001 : T HE U NIVERSAL F LU V ACCINE e.g. T - Helper, CD 4 , CD 8 Produce anti - viral cytokines such as IFN - G IL - 2 Produce Antibodies Directly induces T - Cells T - cell priming effect enhances B - Cell responses Current vaccines mainly induce only flu strain - specific antibodies BiondVax ' s M - 001 Dual Mode of Action M - 001 ' s dual mode of action potentially offers multi - season and multi - strain protection One For All : The Universal Flu Vaccine Cellular (CMI) Works inside infected cells Humoral (HAI) Works outside cells Our immune system has 2 arms: B - cell T - cell

A DVANCED C LINICAL D EVELOPMENT Results Status Total Participants Population (age) Year Trial Phase M - 001 was well tolerated and a cellular (CMI) and humoral (priming effect) immune response was observed Completed 63 Younger Adults (18 - 49) 2009 BVX - 002 1/2 Completed 60 Older Adults (55 - 75) 2010 BVX - 003 1/2 Completed 200 Younger Adults (18 - 49) 2011 BVX - 004 2 Completed 120 Elderly (65+) 2012 BVX - 005 2 Completed 36 Older Adults (50 - 65) 2015 BVX - 006 2 Completed 219 EU Adults (18 - 60) 2015 - 16 BVX - 007 * 2b 698 NIH: 1 st participant enrolled April 2018 120 USA Adults (18 - 49) 2018 BVX - 008 2 4,094 enrolled in 2018 1 st cohort ~10,000 E. European Adults (50+) 2018 BVX - 010 3 One For All : The Universal Flu Vaccine M - 001 : Safe and Immunogenic in Young Adults to Elderly * BVX - 007 was conducted in collaboration with the EU's UNISEC consortium BVX - 008 conducted and led by NIAID/NIH No treatment - related severe adverse events Adverse events were mild to moderate All adverse events observed were transient Immunity: Cellular induced, humoral enhanced Group Day 0 Day 21 Day 42 Treatment M - 001 M - 001 Seasonal or Pandemic HA vaccine to all participants Control Saline Saline HAI CMI Baseline

6.8* 3.8 5.3* 4.7 0.4 * - 0.2 -200 0 200 400 600 800 1000 high INF low INF highIL2 low il2 high tnfa low tnfa Fold change over placebo 0 0.05 0.1 0.15 0.2 0.25 0.3 A/Brisbane/10/07 H3N2 A/California/7/09 H1N1 A/Perth/16/09 H3N2 B/Brisbane/60/08 Flumist 2011 % positive cells (Mean + SE) M-001 twice Day 0 M-001 twice Day 42 * * * * ** M - 001 : I NDUCES C ELL M EDIATED I MMUNITY (CMI) * P<0.05 P<0.07 1 Jacob Atsmon et al. Priming by a novel universal influenza vaccine (Multimeric - 001) - A gateway for improving immune response in the elderly population. Vaccine 32 (2014) 5816 - 5823 Direct Evidence: CD 8 , CD 4 T - cell Activated Cells Produce TH 1 Cytokines (IFN - gamma, IL - 2 & TNF - alpha) BVX005 1 : CD8 & IFN - gamma in Elderly BVX 005 1 : CD 4 & IFN - gamma in Elderly 2.1 * 1.3 13.5 * 6.6 3.5 0 .0 -200 0 200 400 600 800 1000 1200 1400 high any low any high 2/3 low 2/3 high combi low combi Fold change over placebo M - 001 : 1 mg 0.5 mg 1 mg 0.5 mg 1 mg 0.5 mg Single Double Triple UNISEC (EU): 13 fold increase in responders expressing 2 cytokines (18 - 60 Y) IFN - gamma IL - 2 TNF - alpha M - 001: 1mg 0.5mg 1mg 0.5mg 1mg 0.5mg UNISEC (EU): Statistically significant anti viral cytokines * P< 0.05 0 0.05 0.1 0.15 0.2 0.25 0.3 A/Brisbane/10/07 H3N2 A/California/7/09 H1N1 A/Perth/16/09 H3N2 B/Brisbane/60/08 Flumist % positive cells (Mean + SE) M-001 twice Day 0 M-001 twice Day 42 * * 10 8 6 4 2 0 14 12 10 8 6 4 2 0 "Multiple - Cytokine - Producing Antiviral CD4 T Cells Are Functionally Superior to Single - Cytokine - Producing Cells" S Kannanganat et al, J VIROL, 2007, 81(16)8468 - 76

H 1 N 1 pandemic swine flu M - 001: E NHANCES H UMORAL I MMUNITY (HAI) 0 10 20 30 40 50 60 70 TIV 2011/12 M-001 & TIV 2011/12 % Seroprotection (HAI) * "M - 001 can provide broadened enhanced immunity extending even to influenza strains destined to circulate in future years." - Vaccine 2 In 2011 we administered M - 001 to seniors 65+ (BVX005) 4 years later, 5 times more seniors were seroprotected from a new epidemic strain (A/Swiss) that didn't exist in 2011! 1 . Jacob Atsmon et al. Priming by a novel universal influenza vaccine (Multimeric - 001 ) - A gateway for improving immune response in the elderly population. Vaccine 32 ( 2014 ) 5816 - 5823 2 . Lowell GH et al. Back to the future: Immunization with M - 001 prior to trivalent influenza vaccine in 2011 / 12 enhanced protective immune responses against 2014 / 15 epidemic strain. Vaccine ( 2017 ) Indirect Evidence: Extending T - Cell Priming Effect for Enhanced HAI Responses to Current Flu Vaccines BVX 005 1 : 2011 / 12 , age 65 + YO BVX003: 2009, age 55 - 75 YO 0 10 20 30 40 50 60 70 A/California/7/09 A/Perth/16/09 B/Brisbane/60/08 % Seroconversion TIV Twice M-001 + TIV * 0 10 20 30 40 50 60 70 80 A/Brisbane/59/07 A/Brisbane/10/07 B/Brisbane/60/08 % seroconversion TIV Twice M-001 + TIV * P<0.05

M ORE I NFORMATION Articles Atsmon Jacob et al. Priming by a novel universal influenza vaccine (Multimeric - 001) - A gateway for improving immune response in the elderly population. Vaccine 32 (2014) 5816 - 5823 Lowell GH et al. Back to the future: Immunization with M - 001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain. Vaccine (2017) Contact Info Dr. Tamar Ben - Yedidia PhD M - 001 Co - inventor BiondVax Chief Scientific Officer Clinical trials director One For All : The Universal Flu Vaccine

2018: S TARTED P IVOTAL C LINICAL E FFICACY P HASE 3 Trial Design: Flexible enrollment Cohort 1 ( 4,094 enrolled Aug - Oct 2018 ) Cohort 2 ( 6,000 + to be enrolled July - Nov 2019 ) Day 1 Day 21 Day 202 10K+ participants Age 50+ (half 65+) Two flu seasons Results 2 nd H - 2020 Experimental 1mg M - 001 1mg M - 001 Safety, RT - PCR or culture on any ILI (during flu season) Control Placebo Placebo One For All : The Universal Flu Vaccine A pivotal, multicenter, randomized, modified double - blind, placebo - controlled phase 3 trial to assess the safety and clinical efficacy of M - 001 , an influenza vaccine, administered intramuscularly twice in older adults and the elderly ( 50 years of age) ILI symptoms Active surveillance throughout flu seasons Primary Endpoints: Safety & clinical efficacy by reduction of illness rate Secondary Endpoint: Reduced severity of influenza illness

P HASE 3 Cohort 1: 2018/19 Cohort 2: 2019/20 4 countries 54 sites 4,094 participants enrolled 7 countries planned 85 sites planned > 6,000 participants planned One For All : The Universal Flu Vaccine

O NGOING P HASE 2 NIAID sponsored 120 participants (18 - 49 yo ) 3 centers: Houston, Iowa, Cincinnati Trial Design: Spring time - 2 doses (M - 001 or placebo) 3 weeks apart Autumn - standard QIV Endpoints : Safety, T cell responses Details: https://clinicaltrials.gov/ct2/show/NCT03058692 Results: End 2019 anticipated (per NIAID) One For All : The Universal Flu Vaccine

B IOND V AX ' S N EW M ANUFACTURING F ACILITY Funding: EIB, BiondVax, and Israel ' s Ministry of Economy & Industry Target annual capacity: up to 20 million doses in bulk with up to 10 million single dose syringes Goal: Year - round production & stockpile per market demand From Lab to Pilot Mid - Size Commercial Scale Facility (Israel, Aug. 2018 ) One For All : The Universal Flu Vaccine Jerusalem BioPark Hadassah Ein Kerem Campus Jerusalem, Israel

S UMMARY F INANCIAL D ATA Financial Data Highlights Lean structure with 16 employees, current operating burn ~$ 380 K/month (excl. clinical phase 3 trial and facility construction) 6.5 M outstanding ADS ( 8.7 M fully diluted) Balance Sheet Highlights $14.6M cash on hand, no debt (Q3 2018) 20M EIB non - dilutive co - funding agreement 1 received in 2018 Secondary offering Sept 2017, $10M gross proceeds Government of Israel support from Ministry of Economy and Industry's Israel Investment Center, and royalty - based grants from the Israel Innovation Authority (formerly Office of the Chief Scientist) 1 European Investment Bank (EIB) 20 M support for M - 001 Phase 3 trials and commercial production also includes: Milestone based drawdowns. Ultimate milestone included regulatory authorization to launch Phase 3 trial Zero - percent fixed interest loan for five years after each of the 3 drawdowns Variable remuneration based on royalties of net sales BVXV BVXVW American Depository Shares ticker:

F LU V ACCINES - A L ARGE AND G ROWING M ARKET Global Flu Vaccine Sales - 2017 Flu Vaccine Market Seasonal Flu o Worldwide : ~$ 4.3 B global market in 2016 1 ; expected to grow to $ 5.9 B 1,2 by 2021 o US : $ 1.6 B in 2015 growing to $ 2.6 B by 2022 1 ; ~ 175 M doses/year 1 o Forecasted CAGR of > 7 % 2 Pandemic Flu o Swine Flu (A/H 1 N 1 ) 2009 + first half of 2010 sales: ~$ 6.4 B worldwide by Novartis, GSK and Sanofi (on top of seasonal flu vaccine sales) 3 " part of the national strategy for pandemic influenza , the United States ' plan is to stockpile enough pre - pandemic influenza vaccines to cover 20 million in the critical workforce. " 4 " The United States has spent approximately $ 1 billion in these [H 5 N 1 flu vaccine stockpile] efforts to date. " 4 ( 1 ) We assume global sales $ 4 B. http://www.cnbc.com/ 2015 / 10 / 19 /the - 16 - billion - business - of - flu.html ( 2 ) Technavio : 27 Jan 2018 , Source: http://bit.ly/ 2 DJ 6 Mlv ( 3 ) http://www.reports - research.com/news/datamonitor - vaccine - market - overview - 2010 .html [Accessed 20 Nov 2016 ] ( 4 ) http://www.who.int/immunization/sage/meetings/ 2013 /november/SAGE_WG_H 5 vaccine_background_paper_ 16 Oct 2013 _v 4 .pdf ( 5 ) https://www.gsk.com/media/ 4629 /fy - 2017 - results - announcement.pdf [At exchange rate 1.24 ] ( 6 ) https://www.sanofi.com/en/investors/financial - results - and - events/financial - results/Q 4 - results - 2017 / [At exchange rate 1.08 ] ( 7 ) YE June 2018 https://www.csl.com/ - /media/shared/documents/results/ 2018 - fy - analyst.pdf, page 25 ( 8 ) https://www.astrazeneca.com/content/dam/az/PDF/ 2017 /Full - Year/Full - Year% 202017 % 20 Results% 20 announcement% 20 .pdf 2014 / 5 : CSL bought Novartis ' Flu vaccine unit, rebranded to Seqirus $0.60B 5 $ 0.08 B 8 Others ~$0.51B 1 $ 1.09 B 7 $ 1.72 B 6 2017 : Acquired Protein Sciences for $ 750 M GSK 15 % Sanofi 43 % Seqirus 27% 2 % Others 13%

IP: C OMPREHENSIVE AND E XPANDING C OVERAGE 1 =Australia, 2 =Austria, 3 =Belgium, 4 =Brazil, 5 =Canada, 6 =China, 7 =Croatia, 8 =Czech Republic, 9 =Denmark, 10 =Europe, 11 =Finland, 12 =France, 13 =Germany, 14 =Greece, 15 =Hong Kong, 16 =Hungary, 17 =India, 18 =Ireland, 19 =Israel, 20 =Italy, 21 =Japan, 22 =Korea, 23 =Luxembourg, 24 =Mexico, 25 =Netherlands, 26 =New Zealand, 27 =Poland, 28 =Portugal, 29 =Romania, 30 =Russia, 31 =Spain, 32 =Sweden, 33 =Switzerland, 34 =Turkey, 35 =UK, 36 =USA. Expiry Status Priority & Assignee Subject Matter International Publication Title (updated: Nov. 25, 2018) Nov 2019 (Aug 2020 for US) Granted: 1, 3, 5, 12, 13, 15, 19, 20, 22, 24, 25, 26, 31, 33, 35, 36 11/30/1998: Yeda R&D licensed to BiondVax Vaccine comprising different epitopes of the virus WO 00/032228 Peptide - Based Vaccine for Influenza Dec 2026 (Jan 2027 for US) Granted: 1, 2, 3, 5, 9, 12, 13, 14, 18, 19, 20, 23, 25, 28, 31, 32, 33, 35, 36 12/6/2005: Yeda R&D licensed to BiondVax Wide - range vaccines - broad strain and extended protection WO 2007/066334 Improved Influenza Vaccine Aug 2028 (Aug 2031 for US) Granted: 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 Under Examination: 4 8 / 2 / 2007 : BiondVax Vaccines comprising multiple copies of several epitopes - current product WO 2009/016639 Multimeric Multi - Epitope Influenza Vaccines Feb 2031 Granted: 1, 36 Allowed: 5 BiondVax Use of Multimeric as a primer to conventional vaccines WO 2012/114323 Multimeric Multi - Epitope Polypeptides in improved Seasonal and Pandemic Influenza Vaccines April 2035 Filed : 5, 6, 15, 17, 19 Under Examination: 1, 10, 21, 36 4 / 3 / 2014 : BiondVax Production & formulation WO 2015/151103 Vaccine Compositions of Multimeric Multi - epitope Influenza Polypeptides and their Production 74 Patents & 11 Pending Applications Covering polypeptides, polynucleotides , compositions, uses, formulations, production Expiration to 2035

M ANAGEMENT One For All : The Universal Flu Vaccine Ron Babecoff DVM, MEI Tamar Ben - Yedidia PhD Uri Ben - Or CPA, MBA Shimon Hassin PhD Elad Mark BSc Engineering, MBA Joshua Phillipson Hon. BSc Founder, President & CEO CSO & Clinical Trial Leader CFO COO Site Head & Process Development BD Manager Degree from University of Li ge (ULG) Master in Entrepreneurship & Innovation (ISEMI, Swinburne) Omrix Biopharmaceuticals Ltd (Marketing Manager) Dexcel Pharma (Regional Export Manager) Co - inventor of the universal flu vaccine Degree from Weizmann Institute of Science Biotechnology General Ltd. Degree from College of Administration Glycominds Ltd. (VP Finance) Menorah Capital Markets (Comptroller) Degree from University of Maryland Biotechnology Institute Kadimastem (CEO) InSight Biopharmaceuticals (Head of Bioprocessing ) Principal bioprocess engineer Novartis (Technical Project Manager - Process) Hon. BSc. from University of Toronto Accenture (Business Management Consultant) BioData Ltd. (Marketing Manager)

One For All : The Universal Flu Vaccine B OARD OF D IRECTORS Biodar (CEO), Rodar (Founder), Israel Biotech Organization (Chairman, Steering committee) Prof. Avner Rotman, PhD Chairman of the Board Aentib Group (Managing Director), Pluristem (Director). Founder, director, chairman, and/or investor in over twenty biotech companies Mr. Mark Germain Vice Chairman of the Board ID Biomedical (CSO), Intellivax (Founder), Walter Reed General Hospital (Consultant) Dr. George Lowell, MD Director Omrix Pharmaceuticals Ltd (Marketing Manager) , Dexcel Pharma Technologies Ltd. (Formerly Dexxon , Regional Export Manager) Ron Babecoff, DVM, MEI Founder, President and CEO Credit Suisse First Boston (Investment Banking), Private equity and venture capital funds (Founder) Mr. Isaac Devash , MBA Director Linkury Technology International Group (CFO), Union Bank, Spectronix , Biomedix incubator, ADO group, Arko holdings, Algomizer (Director) Mrs. Michal Marom Brikman , CPA Director BioSight Ltd (CEO, Director), SHL Telemedicine (Director), Cellect Biotechnology (Director) Dr. Ruth Ben Yakar , PhD Director BioLineRx (CEO, Director), OurCrowd (Partner), Clil Medical (CEO), Vital Spark (CEO), Kitov Pharmaceuticals (Co - founder, Director) Dr. Morris C. Laster, MD Director

One For All : The Universal Flu Vaccine Contact: Joshua E. Phillipson j.phillipson@biondvax.com +972 - 8 - 930 - 2529 www.biondvax.com 6 completed clinical trials: Safe and immunogenic Ongoing NIAID/NIH sponsored Phase 2 trial Ongoing pivotal, clinical efficacy Phase 3 trial Nasdaq: BVXV

One For All : The Universal Flu Vaccine B IOND V AX ON THE R ADAR More News: http://www.biondvax.com/press - releases/in - the - news/

T HE E LDERLY - A T R ISK AND I N N EED ~ 80 % of seasonal flu related death occurs in elderly 1 Seasonal vaccine effectiveness as low as 9 % for elderly 2 80 % of older adults have at least one chronic condition 3 Influenza worsens outcomes of chronic illness Elderly flu cost in US estimated 4 at $ 56 B per year (hospitalization, mortality, lost earnings) 1 Vaccine journal: www.sciencedirect.com/science/article/pii/S 0264410 X 15002315 , Table 3 ; 2 WHO: http://www.who.int/immunization/research/meetings_workshops/ 2 a_Graham_pdvac_sept 14 .pdf 3 https://www.ncoa.org/healthy - aging/chronic - disease/; 4 Molinari et. al, The annual impact of seasonal influenza in the US, Vaccine 25 ( 2007 ) 5086 - 5096 ; 5 https://academic.oup.com/ije/article/ 35 / 2 / 352 / 694736 ; NIH: " During the period from 1989 to 1997 the vaccination rate for elderly persons 65 years of age in the US increased from 30 to 67% . Despite this increase in coverage, mortality and hospitalization rates continued to increase rather than decline as would be expected ... " International Journal of Epidemiology 5 (Vol. 35, Issue 2, P352 - 353)

C ONTACT I NFORMATION : J OSHUA P HILLIPSON j.phillipson@biondvax.com +972 - 8 - 930 - 2529 www.biondvax.com The Universal Flu Vaccine Multi - Season Multi - Strain Flu Vaccine